MKI.V CURRENT PRICE:
.215
MKI.V TARGET PRICE: $11.33
UPSIDE POTENTIAL: 5,170%
SHARES OUTSTANDING: 57,404,579
February 13, 2012 - Toronto, ON - TSX News reports that
The Medipattern Corporation (TSXV: MKI), a pioneer in the development of medical imaging software solutions that help medical practitioners to better understand lesions and critical anatomy, rose 48% today on news that their FDA approved product
Visualize:Vascular™has been
warmly received by the medical community of the Northeastern United States. Visualize:Vascular™ has been deployed in 20 different hospitals across four states and its target customer base has expanded from vascular surgeons to also include interventional cardiologists, vascular radiologists, general cardiologists, general radiologists and internists.
Medipattern CEO, Jeff Collins stated that
"Revenue on initial quarters will be mainly driven by initial purchases, while per-use renewal license revenue will contribute to successive quarters. To date the per-use business model has been confirmed as customers continue to order license renewals. We expect our revenue to progress as scan volumes increase while customers integrate Visualize:Vascular into their workflow throughout the calendar year."
The Medipattern Corporation (TSXV: MKI), a pioneer in the development of medical imaging software solutions that help medical practitioners to better understand lesions and critical anatomy, has continued to make progress in the commercial rollout of their groundbreaking vascular disease intervention product
Visualize:Vascular™. As confirmed by the CEO, Medipattern's technology has been implemented and used by
19 different health care facilities in the United States.
With 2.6M stock options, MKI has only 60M fully diluted shares outstanding. Given EKG's $1,360M market cap valuation based on their hand-held heart rhythm monitor, it is reasonable to expect that MKI would achieve at least half of the market cap with their medical imaging software solution Visualize:Vascular™ which allows physicians to assess vascular disease in a patient earlier than ever before.
A $680M market cap for MKI would result in a fully diluted stock price of $11.33.
The company is in its final stages before it launches Visualize:Vascular™ nationally across the United States. Based on today's report
TSX News maintains its strong buy target on MKI at $11.33. Medipattern's next major event will be the
Annual Hospital - Physician Leadership Conference MHA in Waltham, MA.